Argenx
| argenx SE | |
|---|---|
| legal form | European society |
| ISIN | NL0010832176 |
| founding | 2008 |
| Seat |
Breda , the Netherlands
|
| management | Tim van Hauwermeiren ( CEO ) |
| Number of employees | 188 |
| sales | 70 million euros |
| Branch | biotechnology |
| Website | www.argenx.com |
| As of December 31, 2019 | |
Argenx is a Dutch biopharmaceutical company with operational headquarters in Zwijnaarde , Belgium , a suburb of Ghent . The company was founded in 2008 and as of June 2020 does not have its own approved pharmaceutical product and has not generated any revenue through product sales up to this point in time. Argenx develops antibody therapies to fight autoimmune diseases and cancer.
Individual evidence
- ↑ Argenx: Board of Directors , accessed June 3, 2020
- ↑ a b Argenx: SEC-Filing Form 20-F , accessed on June 3, 2020
- ↑ Euronext: Company Information , accessed June 3, 2020